Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of “Buy” by Analysts

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have been assigned a consensus rating of “Buy” from the ten research firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $23.00.

Several research analysts recently issued reports on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Chardan Capital reaffirmed a “buy” rating and set a $24.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, February 19th. HC Wainwright increased their target price on shares of Stoke Therapeutics from $35.00 to $47.00 and gave the company a “buy” rating in a report on Tuesday, February 18th. Finally, Needham & Company LLC reissued a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a research report on Tuesday, February 18th.

Stoke Therapeutics Stock Performance

STOK stock opened at $8.50 on Tuesday. The company has a market capitalization of $450.22 million, a P/E ratio of -4.05 and a beta of 0.95. Stoke Therapeutics has a 52-week low of $5.60 and a 52-week high of $17.58. The business has a 50-day simple moving average of $10.47 and a two-hundred day simple moving average of $12.22.

Insider Buying and Selling

In other news, General Counsel Jonathan Allan sold 13,666 shares of the company’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $13.61, for a total transaction of $185,994.26. Following the transaction, the general counsel now owns 21,476 shares of the company’s stock, valued at $292,288.36. This represents a 38.89 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Barry Ticho sold 10,000 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $12.07, for a total value of $120,700.00. Following the transaction, the insider now owns 51,277 shares of the company’s stock, valued at $618,913.39. The trade was a 16.32 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 62,849 shares of company stock valued at $809,421. 11.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Stoke Therapeutics

Several institutional investors have recently added to or reduced their stakes in STOK. KLP Kapitalforvaltning AS purchased a new position in shares of Stoke Therapeutics in the fourth quarter worth about $63,000. Teacher Retirement System of Texas bought a new position in Stoke Therapeutics in the 4th quarter worth approximately $113,000. China Universal Asset Management Co. Ltd. purchased a new position in Stoke Therapeutics in the 4th quarter valued at approximately $124,000. Tower Research Capital LLC TRC raised its holdings in Stoke Therapeutics by 70.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company’s stock valued at $132,000 after acquiring an additional 4,918 shares during the period. Finally, Invesco Ltd. purchased a new stake in shares of Stoke Therapeutics during the fourth quarter worth $133,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.